Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma

BMC Cancer

Gregor Sersa²  Andrej Coer¹  Maja Cemazar¹  Tanja Dolinsek²  Simona Kranjc²  Ales Sedlar² 

[1]Faculty of Health Sciences, University of Primorska, Izola, Slovenia

[2]Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

关键词: Mice;    Sarcoma;    Irradiation;    Gene electrotransfer;    IL-12;   

Others  :  1079952
DOI  :  10.1186/1471-2407-13-38

 received in 2012-07-03, accepted in 2013-01-24,  发布年份 2013

【 摘 要 】

Background

Interleukin-12 (IL-12) based radiosensitization is an effective way of tumor treatment. Local cytokine production, without systemic shedding, might provide clinical benefit in radiation treatment of sarcomas. Therefore, the aim was to stimulate intratumoral IL-12 production by gene electrotransfer of plasmid coding for mouse IL-12 (mIL-12) into the tumors, in order to explore its radiosensitizing effect after single or multiple intratumoral gene electrotransfer.

Methods

Solid SA-1 fibrosarcoma tumors, on the back of A/J mice, were treated intratumorally by mIL-12 gene electrotransfer and 24 h later irradiated with a single dose. Treatment effectiveness was measured by tumor growth delay and local tumor control assay (TCD₅₀ assay). With respect to therapeutic index, skin reaction in the radiation field was scored. The tumor and serum concentrations of cytokines mIL-12 and mouse interferon γ (mIFNγ) were measured. Besides single, also multiple intratumoral mIL-12 gene electrotransfer before and after tumor irradiation was evaluated.

Results

Single intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral but not serum mIL-12 and mIFNγ concentrations, and had good antitumor (7.1% tumor cures) and radiosensitizing effect (21.4% tumor cures). Combined treatment resulted in the radiation dose-modifying factor of 2.16. Multiple mIL-12 gene electrotransfer had an even more pronounced antitumor (50% tumor cures) and radiosensitizing (86.7% tumor cures) effect.

Conclusions

Single or multiple intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral mIL-12 and mIFNγ cytokine level, and may provide an efficient treatment modality for soft tissue sarcoma as single or adjuvant therapy to tumor irradiation.

【 授权许可】

   
2013 Sedlar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies. Strahlenther Onkol 2004, 180:331-339.
• [2]Sersa G, Willingham V, Milas L: Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer 1988, 42:129-134.
• [3]Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
• [4]Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M: Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011, 2:739-751.
• [5]Kamensek U, Sersa G: Targeted gene therapy in radiotherapy. Radiol Oncol 2008, 42:115-135.
• [6]Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Strahlenther Onkol 2004, 180:187–-193.
• [7]Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
• [8]Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY: Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000, 2:195-203.
• [9]Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR: Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol 1999, 15:769-773.
• [10]De Ridder M, Verellen D, Verovski V, Storme G: Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008, 19:164-169.
• [11]Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Yang G, et al.: Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 2007, 14:227-236.
• [12]Kim W, Seong J, Oh HJ, Koom WS, Choi KJ, Yun CO: A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res (Tokyo) 2011, 52:646-654.
• [13]Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, Li CY: Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys 2000, 48:1513-1518.
• [14]Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW, et al.: A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther 2007, 6:380-389.
• [15]Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG: Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig 1998, 6:71-80.
• [16]Teicher BA, Ara G, Menon K, Schaub RG: In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer 1996, 65:80-84.
• [17]Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, Vidic S, Pavlin D, Sersa G: Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009, 11:1125-1137.
• [18]Xian J, Yang H, Lin Y, Liu S: Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2005, 131:1079-1085.
• [19]Yang Y, Liu SZ, Fu SB: Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms. Biomed Environ Sci 2004, 17:135-143.
• [20]Cemazar M, Jarm T, Sersa G: Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010, 10:300-311.
• [21]Heller LC, Heller R: Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010, 10:312-317.
• [22]Kanduser M, Miklavcic D, Pavlin M: Mechanisms involved in gene electrotransfer using high- and low-voltage pulses–an in vitro study. Bioelectrochemistry 2009, 74:265-271.
• [23]Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al.: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008, 26:5896-5903.
• [24]Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N: Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011, 45:31-39.
• [25]Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, Budach W: Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol 2010, 5:55. BioMed Central Full Text
• [26]Kaushal A, Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am 2008, 88:629-646. viii
• [27]Kepka L, DeLaney TF, Suit HD, Goldberg SI: Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005, 63:852-859.
• [28]Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G: Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 2009, 8:2114-2122.
• [29]Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Mesojednik S, Rols MP, Teissie J: Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 2009, 16:635-644.
• [30]Cemazar M, Pavlin D, Kranjc S, Grosel A, Mesojednik S, Sersa G: Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Curr Drug Deliv 2006, 3:77-81.
• [31]Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G: Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat Res 2009, 172:677-685.
• [32]Sersa G, Cemazar M, Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995, 55:3450-3455.
• [33]Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154.
• [34]Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H, Himmelreich U, Stenzel W, Jacobs AH, von Laer D: Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007, 13:6761-6768.
• [35]Sersa G, Kranjc S, Cemazar M: Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 2000, 46:1037-1041.
• [36]Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155-168.
• [37]Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
• [38]Liu SZ, Jin SZ, Liu XD, Sun YM: Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol 2001, 2:8. BioMed Central Full Text
• [39]Lucas ML, Heller L, Coppola D, Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002, 5:668-675.
• [40]Shi X, Cao S, Mitsuhashi M, Xiang Z, Ma X: Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol 2004, 172:4111-4122.
• [41]North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE: Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med 1988, 168:2031-2043.
• [42]Grosel A, Sersa G, Kranjc S, Cemazar M: Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell Biol 2006, 25:674-683.
• [43]Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, Blagus T, Cemazar M, Sersa G: Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012, 46:302-311.
• [44]Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G: Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res 2003, 23:275-281.
• [45]Kranjc S, Cemazar M, Grosel A, Sentjurc M, Sersa G: Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer 2005, 5:115. BioMed Central Full Text
• [46]Raeisi E, Aghamiri SMR, Bandi A, Rahmatpour N, Firoozabadi SM, Kafi-Abad SA, Mir LM: The antitumor efficiency of combined electrochemotherapy and single dose irradiation on a breast cancer tumor model. Radiol Oncol 2012, 46:226-232.